1. Home
  2. XPRO vs ABCL Comparison

XPRO vs ABCL Comparison

Compare XPRO & ABCL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Expro Group Holdings N.V.

XPRO

Expro Group Holdings N.V.

HOLD

Current Price

$15.46

Market Cap

1.9B

Sector

Energy

ML Signal

HOLD

Logo AbCellera Biologics Inc.

ABCL

AbCellera Biologics Inc.

HOLD

Current Price

$6.93

Market Cap

1.6B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
XPRO
ABCL
Founded
1938
2012
Country
United States
Canada
Employees
N/A
N/A
Industry
Oilfield Services/Equipment
Biotechnology: Pharmaceutical Preparations
Sector
Energy
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.9B
1.6B
IPO Year
2013
2020

Fundamental Metrics

Financial Performance
Metric
XPRO
ABCL
Price
$15.46
$6.93
Analyst Decision
Hold
Strong Buy
Analyst Count
5
5
Target Price
$16.00
$8.40
AVG Volume (30 Days)
1.3M
7.4M
Earning Date
05-05-2026
05-11-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
10.91
EPS
N/A
N/A
Revenue
$522,493,000.00
$75,128,000.00
Revenue This Year
$1.86
N/A
Revenue Next Year
$4.70
$21.85
P/E Ratio
N/A
N/A
Revenue Growth
14.89
160.56
52 Week Low
$8.24
$2.75
52 Week High
$18.73
$8.44

Technical Indicators

Market Signals
Indicator
XPRO
ABCL
Relative Strength Index (RSI) 54.45 52.74
Support Level $12.80 $3.38
Resistance Level $17.11 N/A
Average True Range (ATR) 0.57 0.71
MACD 0.17 -0.04
Stochastic Oscillator 97.77 43.60

Price Performance

Historical Comparison
XPRO
ABCL

About XPRO Expro Group Holdings N.V.

Expro Group Holdings NV offers products and services that span the well life cycle, including well construction, well flow management, well intervention and integrity, and subsea well access. It maintains operations around the world and specializes in offshore production solutions. It also provides production optimization for both onshore and offshore applications. The company has four operating segments: North and Latin America (NLA); Europe and Sub-Saharan Africa (ESSA); Middle East and North Africa (MENA); and Asia-Pacific (APAC). The majority of its revenue is derived from the North and Latin America (NLA) segment.

About ABCL AbCellera Biologics Inc.

AbCellera Biologics Inc is a clinical-stage biotechnology company focused on discovering and developing first-in-class antibody medicines for indications with high unmet medical need. It has built a platform for advancing antibody drug programs that the company believes provides it with a competitive advantage in addressing challenging, high-value targets such as complex transmembrane proteins and novel modalities, including multispecifics and antibody-drug conjugates. Organisation's pipeline includes two drug candidates in clinical development, two development candidates in Investigational New Drug (IND/Clinical Trial Application (CTA)-enabling activities, and more than 20 active discovery programs across multiple modalities and indications.

Share on Social Networks: